Kaan Karamık, Mahmut Taha Ölçücü, Yiğit Demir, Mehmet Reşat İnal, Hakan Anıl, Kayhan Yılmaz, Mutlu Ateş
Bulletin of Urooncology - 2025;24(4):97-102
Objective: The purpose of study was to identify the clinical utility of preoperative systemic immune-inflammation index (SII) in predicting biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective analysis was performed using data from our robotic surgery database, which included 531 patients with localized prostate cancer (PCa) who received RARP from March 2015 through June 2021. Patients' characteristics and outcomes were recorded. The preoperative SII of each patient was calculated. Patients with and without BCR were confronted. The predictive ability of the SII was determined by receiver operating characteristic (ROC) curve analysis. Results: After applying the exclusion criteria, the study included 400 patients. Among them, 90 patients (22.5%) experienced BCR. Analysis of the relationship between BCR and preoperative variables demonstrated that prostate-specific antigen, biopsy International Society of Urological Pathology (ISUP) grade, clinical stage, and D'Amico classification statistically significant. Although the SII was higher in patients with BCR, the difference was not statistically significant (p=0.198). Previously reported pathological factors, such as ISUP grade at prostatectomy, pathological stage, lymphovascular invasion, perineural invasion, extraprostatic extension, seminal vesicle invasion, and positive surgical margin, were associated with BCR. The ROC curve for the SII demonstrated poor predictive ability for BCR (95% confidence interval: 0.412-0.545; p=0.532). Conclusion: SII did not appear to be a prognostic indicator for BCR after RARP in localized PCa patients.
